DGAP-News

Novavax Reports Second-Quarter 2014 Financial Results

DGAP-News: Novavax, Inc.
Novavax Reports Second-Quarter 2014 Financial Results

06.08.2014 / 22:27

---------------------------------------------------------------------

GAITHERSBURG, Md., 2014-08-06 22:27 CEST (GLOBE NEWSWIRE) --
Novavax, Inc. (Nasdaq:NVAX), a clinical-stage biopharmaceutical company focused
on the discovery, development and commercialization of recombinant nanoparticle
vaccines and adjuvants, today reported its financial results for the second
quarter and six months ended June 30, 2014.

Novavax Corporate Highlights

Second Quarter Achievements:

- Delivered positive top-line data from a dose-confirmatory Phase 2 clinical
trial of its RSV F-protein vaccine candidate in 720 women of childbearing age,
including a key finding that the highest levels of Palivizumab-competing
antibodies (PCA) observed in any of its previous trials was achieved with only
one dose of its vaccine candidate;

- Reported follow-up data from its dose-ranging Phase 1 clinical trial of its
RSV F-protein vaccine candidate in 220 elderly subjects, showing sustained
levels of RSV F antibody and PCA responses were demonstrated over a four to six
month period; and

- Raised total net-proceeds of $108 million, after deducting underwriters
discount and offering expenses, in an underwritten public offering.

2014 Anticipated Events:

- Release of top-line data from recently initiated Phase 1/2 clinical trial of
H7N9 avian influenza VLP vaccine candidate with its Matrix-M adjuvant in the
third quarter of 2014;

- Initiate Phase 2 clinical trial of its RSV F-protein vaccine candidate for
protection of infants via maternal immunization in pregnant women in fourth
quarter of 2014;

- Initiate Phase 1 clinical trial of its RSV F-protein vaccine candidate for
protection of pediatrics in fourth quarter of 2014;

- Initiate Phase 2 clinical trial of its RSV F-protein vaccine candidate for
protection of elderly in fourth quarter of 2014;

- Initiate Phase 2 clinical trial of its quadrivalent VLP seasonal influenza
vaccine in the fourth quarter of 2014;

- Novavax, Inc. 2014 Analyst and Investor Meeting to be held on Tuesday,
September 23, 2014 in New York City; and

- Novavax will present the following pre-clinical data at the upcoming ICAAC
conference to be held in Washington, DC between September 5 - 9, 2014:

-- Presentation # I-649: 'Immunization of Pregnant Baboons with the RSV
Nanoparticle Vaccine Protects Infant Baboons Challenged with Respiratory
Syncytial Virus in a Comparable Manner to Infants Prophylaxed with
Palivizumab;' and
-- Presentation # I-314B: 'Development and Characterization of Recombinant RSV
Nanoparticle Vaccine Induced Monoclonal Antibody.'